PYHIN1

Summary

PYHIN1 (pyrin and HIN domain family member 1, HGNC:28894) is a protein-coding gene on chromosome 1q23.1, encoding Pyrin and HIN domain-containing protein 1 (Q6K0P9). Major mediator of the tumor suppressor activity of IFN in breast cancer cells.

The protein encoded by this gene belongs to the HIN-200 family of interferon-inducible proteins that share a 200-amino acid signature motif at their C-termini. HIN200 proteins are primarily nuclear and are involved in transcriptional regulation of genes important for cell cycle control, differentiation, and apoptosis. Downregulation of this gene is associated with breast cancer. This protein acts as a tumor suppressor by promoting ubiquitination and subsequent degradation of MDM2, which leads to stabilization of p53/TP53. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 149628 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 62 total
• MANE Select transcript: NM_152501

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28894
Approved symbol	PYHIN1
Name	pyrin and HIN domain family member 1
Location	1q23.1
Locus type	gene with protein product
Status	Approved
Aliases	IFIX, MGC23885
Ensembl gene	ENSG00000163564
Ensembl biotype	protein_coding
OMIM	612677
Entrez	149628

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000368135, ENST00000368138, ENST00000368140, ENST00000392252, ENST00000392254, ENST00000458222, ENST00000485134

RefSeq mRNA: 5 — MANE Select: NM_152501 NM_001410886, NM_152501, NM_198928, NM_198929, NM_198930

CCDS: CCDS1178, CCDS1179, CCDS30907, CCDS30908, CCDS91077

Canonical transcript exons

ENST00000368140 — 9 exons

Exon	Start	End
ENSE00001076006	158938397	158938542
ENSE00001380490	158973647	158973771
ENSE00001383959	158944875	158945042
ENSE00001446405	158931552	158931776
ENSE00001632728	158976701	158977059
ENSE00002382769	158939080	158939247
ENSE00002387824	158936891	158937175
ENSE00003622783	158941977	158942399
ENSE00003692892	158943790	158943978

Expression profiles

Bgee: expression breadth ubiquitous, 168 present calls, max score 93.35.

FANTOM5 (CAGE): breadth broad, TPM avg 5.7239 / max 498.4989, expressed in 254 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
5914	5.3003	244
5913	0.1450	54
5915	0.1394	60
5911	0.1009	44
5912	0.0382	21

Top tissues by expression

271 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	93.35	gold quality
blood	UBERON:0000178	87.36	gold quality
lymph node	UBERON:0000029	86.14	gold quality
spleen	UBERON:0002106	82.50	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.38	gold quality
buccal mucosa cell	CL:0002336	81.34	gold quality
vermiform appendix	UBERON:0001154	77.38	gold quality
superficial temporal artery	UBERON:0001614	76.42	gold quality
gall bladder	UBERON:0002110	74.61	gold quality
epithelium of nasopharynx	UBERON:0001951	74.45	gold quality
tonsil	UBERON:0002372	73.19	gold quality
diaphragm	UBERON:0001103	73.12	gold quality
caecum	UBERON:0001153	72.58	gold quality
olfactory bulb	UBERON:0002264	71.53	gold quality
small intestine Peyer’s patch	UBERON:0003454	71.49	gold quality
type B pancreatic cell	CL:0000169	71.36	gold quality
bone marrow cell	CL:0002092	71.23	gold quality
upper lobe of left lung	UBERON:0008952	70.76	gold quality
mucosa of transverse colon	UBERON:0004991	69.75	gold quality
upper lobe of lung	UBERON:0008948	69.75	gold quality
right lung	UBERON:0002167	69.57	gold quality
rectum	UBERON:0001052	69.51	gold quality
omental fat pad	UBERON:0010414	69.38	gold quality
peritoneum	UBERON:0002358	69.30	gold quality
small intestine	UBERON:0002108	69.20	gold quality
bone marrow	UBERON:0002371	69.17	gold quality
leukocyte	CL:0000738	69.08	gold quality
adipose tissue of abdominal region	UBERON:0007808	68.74	gold quality
right lobe of liver	UBERON:0001114	67.96	gold quality
colonic epithelium	UBERON:0000397	67.59	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 9.

Experiment	Marker?	Max mean expression
E-HCAD-1	yes	101.05
E-MTAB-9467	yes	39.28
E-CURD-122	yes	39.21
E-HCAD-10	yes	27.19
E-ANND-3	yes	23.57
E-MTAB-10553	yes	13.63
E-MTAB-6678	yes	10.31
E-MTAB-9067	yes	5.73
E-GEOD-130148	yes	4.89
E-GEOD-75367	no	382.93
E-CURD-112	no	3.70

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
HDAC1	Repression
SERPINB5	Activation

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

54 targeting PYHIN1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488

Literature-anchored findings (GeneRIF, showing 5)

• a new member of the hematopoietic interferon (IFN)-inducible nuclear protein. Six different alternatively spliced forms are transcribed from the IFIX gene (PMID:15122330)
• IFIX alpha1 isoform functions as a tumor suppressor by repressing HDM2 function (PMID:16479015)
• IFIXalpha suppressed the invasion activity of MDA-MB-468 breast cancer cells, and its inhibitory effect was reversed by the knockdown of maspin (PMID:18247378)
• Study demonstrates that IFIX antiviral functions work in part via viral transcriptional suppression and that HSV-1 has acquired mechanisms to block its functions via proteasome-dependent degradation. (PMID:28077445)
• PYHIN1 regulates pro-inflammatory cytokine induction rather than innate immune DNA sensing in airway epithelial cells. (PMID:32102850)

Cross-species orthologs

0 orthologs

Paralogs (3): MNDA (ENSG00000163563), IFI16 (ENSG00000163565), AIM2 (ENSG00000163568)

Protein

Protein identifiers

Pyrin and HIN domain-containing protein 1 — Q6K0P9 (reviewed: Q6K0P9)

Alternative names: Interferon-inducible protein X

All UniProt accessions (2): Q6K0P9, X6RHR0

UniProt curated annotations — full annotation on UniProt →

Function. Major mediator of the tumor suppressor activity of IFN in breast cancer cells. Promotes ubiquitination and subsequent degradation of MDM2, which leads to p53/TP53 stabilization. Promotes ubiquitination and subsequent degradation of HDAC1, which in turn enhances maspin expression, and impairs invasive activity of cancer cells.

Subunit / interactions. Interacts with MDM2.

Subcellular location. Nucleus. Nucleoplasm Nucleus. Nucleus speckle.

Tissue specificity. Expressed in spleen, lymph node and peripheral blood leukocytes, and at lower levels in thymus, bone marrow and fetal liver. Down-regulated in breast tumors.

Domain organisation. The HIN-200 domain mediates interaction with MDM2.

Induction. By IFN-alphas and IFNG/IFN-gamma in hematopoietic cancer cells.

Similarity. Belongs to the HIN-200 family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q6K0P9-1	1, alpha1	yes
Q6K0P9-2	2, alpha2
Q6K0P9-3	3, beta1
Q6K0P9-4	4, beta2
Q6K0P9-5	5, gamma1
Q6K0P9-6	6, gamma2

RefSeq proteins (5): NP_001397815, NP_689714, NP_945146, NP_945147, NP_945148 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004020	DAPIN	Domain
IPR004021	HIN200/IF120x	Domain
IPR011029	DEATH-like_dom_sf	Homologous_superfamily
IPR012340	NA-bd_OB-fold	Homologous_superfamily
IPR040205	HIN-200	Family

Pfam: PF02758, PF02760

UniProt features (14 total): compositionally biased region 5, splice variant 4, domain 2, region of interest 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6K0P9-F1	72.76	0.52

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 164 (showing top): GOBP_POSITIVE_REGULATION_OF_DNA_DAMAGE_RESPONSE_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR, GOBP_RESPONSE_TO_PEPTIDE, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_REGULATION_OF_DNA_DAMAGE_RESPONSE_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR, GOBP_RESPONSE_TO_INTERFERON_BETA, GOBP_RESPONSE_TO_INTERFERON_ALPHA, GOBP_POSITIVE_REGULATION_OF_BINDING, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION_TO_NUCLEUS, GOBP_POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_PROTEIN_DESTABILIZATION, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM

GO Biological Process (10): activation of innate immune response (GO:0002218), protein destabilization (GO:0031648), cellular response to interferon-alpha (GO:0035457), cellular response to interferon-beta (GO:0035458), positive regulation of DNA binding (GO:0043388), positive regulation of DNA damage response, signal transduction by p53 class mediator (GO:0043517), positive regulation of DNA-templated transcription (GO:0045893), protein stabilization (GO:0050821), positive regulation of protein localization to nucleus (GO:1900182), positive regulation of ubiquitin-dependent protein catabolic process (GO:2000060)

GO Molecular Function (2): double-stranded DNA binding (GO:0003690), ubiquitin protein ligase binding (GO:0031625)

GO Cellular Component (6): nucleoplasm (GO:0005654), nucleolus (GO:0005730), cytosol (GO:0005829), nuclear speck (GO:0016607), protein-containing complex (GO:0032991), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of protein stability	2
cellular response to cytokine stimulus	2
DNA binding	2
nuclear lumen	2
cellular anatomical structure	2
activation of immune response	1
positive regulation of innate immune response	1
response to interferon-alpha	1
response to interferon-beta	1
positive regulation of binding	1
regulation of DNA binding	1
DNA damage response, signal transduction by p53 class mediator	1
regulation of DNA damage response, signal transduction by p53 class mediator	1
positive regulation of signal transduction by p53 class mediator	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
protein localization to nucleus	1
regulation of protein localization to nucleus	1
positive regulation of protein localization	1
ubiquitin-dependent protein catabolic process	1
positive regulation of protein catabolic process	1
regulation of ubiquitin-dependent protein catabolic process	1
ubiquitin-like protein ligase binding	1
intracellular membraneless organelle	1
cytoplasm	1
nuclear ribonucleoprotein granule	1
cellular_component	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1330 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PYHIN1	MEFV	O15553	778
PYHIN1	SERPINB5	P36952	585
PYHIN1	PYCARD	Q9ULZ3	531
PYHIN1	ORMDL3	Q8N138	507
PYHIN1	DENND1B	Q6P3S1	480
PYHIN1	GSDMB	Q8TAX9	479
PYHIN1	GBP3	Q9H0R5	462
PYHIN1	IFIT3	O14879	461
PYHIN1	CMPK2	Q5EBM0	455
PYHIN1	CGAS	Q8N884	454
PYHIN1	XAF1	Q6GPH4	447
PYHIN1	DDX41	Q9UJV9	445
PYHIN1	GBP6	Q6ZN66	437
PYHIN1	SUMO2	P55855	430
PYHIN1	IFIT2	P09913	425

IntAct

7 interactions, top by confidence:

A	B	Type	Score
	PYHIN1	psi-mi:“MI:0407”(direct interaction)	0.540
PYHIN1		psi-mi:“MI:0915”(physical association)	0.540
UL83	PYHIN1	psi-mi:“MI:0915”(physical association)	0.400
PYHIN1	DUSP14	psi-mi:“MI:0914”(association)	0.350
PYHIN1	SUPT5H	psi-mi:“MI:0914”(association)	0.350
	PYHIN1	psi-mi:“MI:0403”(colocalization)	0.270

BioGRID (431): TRIM26 (Affinity Capture-MS), SERPINB5 (Affinity Capture-MS), CALML3 (Affinity Capture-MS), VPRBP (Affinity Capture-MS), LYG2 (Affinity Capture-MS), S100A3 (Affinity Capture-MS), PLCD1 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), HEPHL1 (Affinity Capture-MS), LGALS3 (Affinity Capture-MS), VSIG8 (Affinity Capture-MS), DSG4 (Affinity Capture-MS), NEU2 (Affinity Capture-MS), AIM1 (Affinity Capture-MS), FAM26D (Affinity Capture-MS)

ESM2 similar proteins: A6H5X4, B1AUS7, D0QMC3, O35368, O60224, O60225, P0C6Y7, P0DOV1, P0DOV2, P23497, P41218, Q15361, Q16384, Q16385, Q16666, Q2KIN0, Q3U827, Q3ZCI6, Q4R7Q1, Q504N7, Q5H9L4, Q5I0E2, Q5I0J8, Q5RAK3, Q5RCZ8, Q5RD14, Q5W0A0, Q62187, Q6K0P9, Q71F23, Q7RTT3, Q7RTT4, Q7RTT5, Q7RTT6, Q86T96, Q8BV49, Q8BVM9, Q8C0V1, Q8C6C7, Q8CGE8

Diamond homologs: D0QMC3, O14862, O35368, P0DOV1, P0DOV2, P41218, Q16666, Q3V3Q4, Q504N7, Q5RD14, Q6K0P9, Q8BV49, Q8CGE8, Q8SPH9, Q91VJ1, Q9R002, W6CW81

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PYHIN1	“down-regulates quantity by destabilization”	MDM2	binding
PYHIN1	“down-regulates quantity by repression”	HDAC1	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	9
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

989 predictions. Top by Δscore:

Variant	Effect	Δscore
1:158931772:GTAAG:G	donor_gain	1.0000
1:158931777:G:GG	donor_gain	1.0000
1:158943786:GCA:G	acceptor_loss	1.0000
1:158943788:A:AG	acceptor_gain	1.0000
1:158943788:A:C	acceptor_loss	1.0000
1:158943789:G:GG	acceptor_gain	1.0000
1:158943789:GA:G	acceptor_gain	1.0000
1:158943789:GAA:G	acceptor_gain	1.0000
1:158943789:GAAA:G	acceptor_gain	1.0000
1:158943789:GAAAA:G	acceptor_gain	1.0000
1:158943893:GAGA:G	donor_gain	1.0000
1:158943975:CCAG:C	donor_loss	1.0000
1:158943976:CAG:C	donor_loss	1.0000
1:158943979:GTGAG:G	donor_loss	1.0000
1:158943980:T:A	donor_loss	1.0000
1:158931773:TAAG:T	donor_gain	0.9900
1:158931775:AGGTG:A	donor_loss	0.9900
1:158931776:GGTG:G	donor_loss	0.9900
1:158931777:G:GA	donor_loss	0.9900
1:158931778:T:G	donor_loss	0.9900
1:158938393:T:G	acceptor_gain	0.9900
1:158938395:A:AG	acceptor_gain	0.9900
1:158938396:G:GG	acceptor_gain	0.9900
1:158938396:GTT:G	acceptor_gain	0.9900
1:158939079:GAAAA:G	acceptor_gain	0.9900
1:158941963:T:TA	acceptor_gain	0.9900
1:158941967:T:G	acceptor_gain	0.9900
1:158943783:GTTGC:G	acceptor_loss	0.9900
1:158943896:A:G	donor_gain	0.9900
1:158943934:G:T	donor_gain	0.9900

AlphaMissense

3242 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:158943967:A:C	S394R	0.993
1:158943969:T:A	S394R	0.993
1:158943969:T:G	S394R	0.993
1:158942184:T:C	F263L	0.989
1:158942186:C:A	F263L	0.989
1:158942186:C:G	F263L	0.989
1:158942112:T:C	F239L	0.987
1:158942114:T:A	F239L	0.987
1:158942114:T:G	F239L	0.987
1:158942118:G:C	A241P	0.986
1:158943916:T:C	F377L	0.986
1:158943918:T:A	F377L	0.986
1:158943918:T:G	F377L	0.986
1:158942185:T:C	F263S	0.984
1:158937076:T:C	F56L	0.979
1:158937078:C:A	F56L	0.979
1:158937078:C:G	F56L	0.979
1:158943817:T:G	Y344D	0.977
1:158943917:T:C	F377S	0.977
1:158937055:G:C	A49P	0.975
1:158942113:T:C	F239S	0.975
1:158942119:C:A	A241D	0.975
1:158942385:T:C	F330L	0.975
1:158942387:T:A	F330L	0.975
1:158942387:T:G	F330L	0.975
1:158943968:G:T	S394I	0.970
1:158942073:T:C	F226L	0.967
1:158942075:T:A	F226L	0.967
1:158942075:T:G	F226L	0.967
1:158937056:C:A	A49D	0.964

dbSNP variants (sampled 300 via entrez): RS1000009592 (1:158986313 G>C), RS1000155565 (1:158947315 T>C), RS1000176095 (1:158989381 C>G), RS1000194296 (1:158936040 T>C), RS1000205795 (1:158956976 C>G), RS1000231402 (1:158983113 C>G), RS1000277345 (1:158939547 C>T), RS1000366495 (1:158933494 C>T), RS1000419111 (1:158933244 A>G), RS1000438624 (1:158947666 A>C), RS1000475506 (1:158986022 TA>T), RS1000484033 (1:158961783 G>A), RS1000494262 (1:158966145 A>C,G), RS1000590654 (1:158953525 C>A,T), RS1000660815 (1:158952903 T>A)

Disease associations

OMIM: gene MIM:612677 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001182_7	Asthma	4.000000e-09
GCST002743_1	Neutrophil count in HIV-infection	3.000000e-06
GCST009269_21	Dental caries (decayed and filled deciduous teeth)	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004833	neutrophil count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Absent in melanoma (AIM)-like receptors (ALRs)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, increases methylation	2
Dinitrochlorobenzene	affects binding, decreases expression	2
Formaldehyde	decreases expression, increases expression	2
triphenyl phosphate	affects expression	1
sodium arsenite	affects methylation	1
nickel sulfate	decreases expression	1
hydroquinone	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
CGP 52608	affects binding, increases reaction	1
nutlin 3	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Demecolcine	increases expression	1
Diethylhexyl Phthalate	increases expression	1
Ethyl Methanesulfonate	increases expression	1
Lipopolysaccharides	affects response to substance, increases expression, decreases expression	1
Methyl Methanesulfonate	increases expression	1
N-Nitrosopyrrolidine	increases expression	1
Nickel	increases expression	1
Oxazolone	decreases expression	1
Vincristine	increases expression	1
Aflatoxin B1	increases expression	1
Antirheumatic Agents	decreases expression	1
Okadaic Acid	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1H5	Abcam A-549 PYHIN1 KO 1	Cancer cell line	Male
CVCL_B2PP	Abcam A-549 PYHIN1 KO 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer